Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai,Craig M. Crews +1 more
TLDR
Induced protein degradation has the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins.Abstract:
Small-molecule drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function, and this approach typically precludes targeting proteins that lack such amenable sites. Furthermore, high systemic drug exposures may be needed to maintain sufficient target inhibition in vivo, increasing the risk of undesirable off-target effects. Induced protein degradation is an alternative approach that is event-driven: upon drug binding, the target protein is tagged for elimination. Emerging technologies based on proteolysis-targeting chimaeras (PROTACs) that exploit cellular quality control machinery to selectively degrade target proteins are attracting considerable attention in the pharmaceutical industry owing to the advantages they could offer over traditional small-molecule strategies. These advantages include the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins.read more
Citations
More filters
Journal ArticleDOI
Structural basis of PROTAC cooperative recognition for selective protein degradation.
M.S. Gadd,Andrea Testa,Xavier Lucas,Kwok-Ho Chan,Wenzhang Chen,Douglas J. Lamont,Michael Zengerle,Alessio Ciulli +7 more
TL;DR: The results elucidate how PROTAC-induced de novo contacts dictate preferential recruitment of a target protein into a stable and cooperative complex with an E3 ligase for selective degradation.
Journal ArticleDOI
Kinase inhibitors: the road ahead
TL;DR: An overview of the novel targets, biological processes and disease areas that kinase-targeting small molecules are being developed against, highlight the associated challenges and assess the strategies and technologies that are enabling efficient generation of highly optimized kinase inhibitors are provided.
Journal ArticleDOI
Drugging the 'undruggable' cancer targets
TL;DR: Four scientists working in the 'undruggable' cancer research field are asked for their opinions on the most crucial advances, as well as the challenges and what the future holds for this important area of research.
Journal ArticleDOI
Targeting transcription factors in cancer - from undruggable to reality.
TL;DR: This Review discusses the various approaches that are being explored to target transcription factors in cancer, with many of the inhibitors developed from such approaches now advancing to early clinical trials.
Journal ArticleDOI
Expanding the medicinal chemistry synthetic toolbox
TL;DR: Opportunities for the expansion of the medicinal chemists' synthetic toolbox are highlighted to enable enhanced impact of new methodologies in future drug discovery.
References
More filters
Identification and characterization of essential genes in the human genome
Timothy C. Wang,Kıvanç Birsoy,Nicholas W. Hughes,Kevin M. Krupczak,Yorick Post,Yorick Post,Jenny J. Wei,Eric S. Lander,Eric S. Lander,Eric S. Lander,David M. Sabatini +10 more
TL;DR: A genome-wide single-guide RNA library is constructed to screen for genes required for proliferation and survival in a human cancer cell line and reveals a set of cell-essential genes, which was validated with an orthogonal gene-trap–based screen and comparison with yeast gene knockouts.
Journal ArticleDOI
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
Thomas O'Hare,Denise K. Walters,Eric P. Stoffregen,Taiping Jia,Paul W. Manley,Jürgen Mestan,Sandra W. Cowan-Jacob,Francis Y. Lee,Michael Heinrich,Michael W. Deininger,Brian J. Druker,Brian J. Druker +11 more
TL;DR: It is reported that AMN107 and BMS-354825 are 20-fold and 325-fold more potent than imatinib against cells expressing wild-type Bcr-Abl and that similar improvements are maintained for allImatinib-resistant mutants tested, with the exception of T315I.
Journal ArticleDOI
Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53
TL;DR: Mdm2 is a ubiquitin protein ligase (E3) for p53 and that its activity is dependent on its RING finger, and it is shown that Mdm2 mediates its own ubiquitination in a Ringing finger-dependent manner, which requires no eukaryotic proteins other than ubiquitIn-activating enzyme (E1) and an ubiquit in-conjugating enzyme(E2).
Journal ArticleDOI
Impact of high-throughput screening in biomedical research
Ricardo Macarron,Martyn Banks,Dejan Bojanic,David J. Burns,Dragan A. Cirovic,Tina Garyantes,Darren V. S. Green,Robert P. Hertzberg,William P. Janzen,Jeff W. Paslay,Ulrich Schopfer,G. Sitta Sittampalam +11 more
TL;DR: The case for the use of HTS as part of a proven scientific tool kit, the wider use of which is essential for the discovery of new chemotypes is presented.
Journal ArticleDOI
MDM2, MDMX and p53 in oncogenesis and cancer therapy.
TL;DR: This Review highlights the progress made and pitfalls encountered as the field continues to search for MDM-targeted antitumour agents.
Related Papers (5)
Catalytic in vivo protein knockdown by small-molecule PROTACs
Daniel P. Bondeson,Alina Mares,Ian Edward David Smith,Ko Eunhwa,Sebastien Andre Campos,Afjal Hussain Miah,Katie E Mulholland,Natasha Routly,Dennis L. Buckley,Jeffrey L. Gustafson,Nico Zinn,Paola Grandi,Satoko Shimamura,Giovanna Bergamini,Maria Faelth-Savitski,Marcus Bantscheff,Carly S. Cox,Deborah A. Gordon,Ryan R. Willard,John J. Flanagan,Linda N. Casillas,Bartholomew J. Votta,Willem den Besten,Kristoffer Famm,Laurens Kruidenier,Paul S. Carter,John D. Harling,Ian Churcher,Craig M. Crews +28 more